Knee research advances

Two knee research efforts moved forward this week: a mid-stage drug trial reported less osteoarthritis pain, and Scripps Health landed $12.7 million for injury-repair work. (thelancet.com) (scripps.org) Knee osteoarthritis happens when joint tissue wears down and the knee becomes painful and stiff; the World Health Organization says the knee is the joint most often affected worldwide. In the United States, osteoarthritis affects about 33 million adults, according to the Arthritis Foundation. (who.int) (arthritis.org) The drug candidate, LEVI-04, is designed like a molecular sponge: it binds excess neurotrophin-3, a pain-signaling protein linked to osteoarthritis, using a p75 neurotrophin receptor fusion protein. Levicept says the aim is pain relief without the rapid joint damage seen with some earlier nerve-growth-factor-blocking drugs. (levicept.com) (academic.oup.com) In the phase 2 trial, 518 people with painful, X-ray-confirmed knee osteoarthritis were randomly assigned to placebo or LEVI-04 at 0.3, 1, or 2 milligrams per kilogram every four weeks through week 16. The study started on October 19, 2022, and reached primary completion on May 20, 2024, according to ClinicalTrials.gov. (clinicaltrials.gov) (academic.oup.com) Researchers reported statistically significant improvements in pain and function at weeks 5 and 17 versus placebo across all three dose groups. More than half of treated patients had at least a 50% pain reduction, and more than a quarter had at least a 75% reduction at those time points. (academic.oup.com) (thelancet.com) Safety has been a central issue in this field because earlier pain drugs aimed at related pathways were tied to rapidly progressive osteoarthritis, a form of sudden joint breakdown. In the LEVI-04 study, investigators reported no increase in serious adverse events, treatment-emergent adverse events, or rapidly progressive osteoarthritis versus placebo. (academic.oup.com) (levicept.com) A separate line of research is targeting knee injuries before they become end-stage joint disease. On April 13, 2026, Scripps Health said the California Institute for Regenerative Medicine awarded it $12.7 million for preclinical work on stem-cell-derived cartilage and bone tissue that could be implanted to repair some knee defects. (scripps.org) (timesofsandiego.com) That Scripps program will test “scaffold-free” tissue, meaning the cells are grown into repair tissue without the fiber framework often used as a support structure. The work will include laboratory tissue engineering and animal-model surgeries led by investigators at the Shiley Center for Orthopaedic Research and Education at Scripps Clinic. (scripps.org) (beckersspine.com) Scripps said it plans to use the five-year grant period to prepare an investigational new drug or biologic application for the Food and Drug Administration. If regulators clear that filing, the health system could move into human clinical trials. (scripps.org) (timesofsandiego.com) The two projects address different parts of the same problem: one aims to lower pain in damaged knees, and the other aims to rebuild injured cartilage and bone before replacement surgery is needed. Scripps cited prior research estimating about 900,000 knee cartilage injuries and more than 200,000 related surgeries each year in the United States. (thelancet.com) (scripps.org)